Insights into natriuretic peptides in heart failure: An update View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-06

AUTHORS

Josef Korinek, Guido Boerrigter, Selma F. Mohammed, John C. Burnett

ABSTRACT

Natriuretic peptides (NPs) secreted by the heart in response to volume overload are pleiotropic molecules with vasodilating, diuretic, natriuretic, antiproliferative, and antifibrotic actions. Functioning of the NP system is altered in congestive heart failure (CHF), suggesting that support of the NP system might be beneficial in treatment of acute and chronic CHF. Several approaches alone or in combination with other pharmacologic therapies have been shown to enhance function of the NP system: direct administration of native and designer NPs, inhibition of degradation of NPs and their second messenger (cyclic guanosine monophosphate [cGMP]), and stimulation of cGMP generation. Despite increasing numbers of studies using NPs in therapy of acute and chronic CHF, several controversies regarding safety, efficacy, and dosing of NPs need to be addressed. Moreover, further research is warranted to identify the stages and etiologies of CHF that may profit from NP therapy. More... »

PAGES

97-104

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11897-008-0016-y

DOI

http://dx.doi.org/10.1007/s11897-008-0016-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1038509334

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18765080


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chronic Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclic GMP", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Natriuretic Peptide, Brain", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Natriuretic Peptide, C-Type", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Natriuretic Peptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Renin-Angiotensin System", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sensitivity and Specificity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Mayo Clinic and Foundation, 200 First Street SW, 55905, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Mayo Clinic and Foundation, 200 First Street SW, 55905, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Korinek", 
        "givenName": "Josef", 
        "id": "sg:person.0753213563.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753213563.81"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Boerrigter", 
        "givenName": "Guido", 
        "id": "sg:person.01021616027.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021616027.74"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Mohammed", 
        "givenName": "Selma F.", 
        "id": "sg:person.0646060617.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646060617.69"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Burnett", 
        "givenName": "John C.", 
        "id": "sg:person.01001266776.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001266776.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/b:pham.0000048203.30568.81", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004340827", 
          "https://doi.org/10.1023/b:pham.0000048203.30568.81"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nbt1199", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015601292", 
          "https://doi.org/10.1038/nbt1199"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11095-007-9286-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019200894", 
          "https://doi.org/10.1007/s11095-007-9286-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2399", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051687311", 
          "https://doi.org/10.1038/nrd2399"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-06", 
    "datePublishedReg": "2008-06-01", 
    "description": "Natriuretic peptides (NPs) secreted by the heart in response to volume overload are pleiotropic molecules with vasodilating, diuretic, natriuretic, antiproliferative, and antifibrotic actions. Functioning of the NP system is altered in congestive heart failure (CHF), suggesting that support of the NP system might be beneficial in treatment of acute and chronic CHF. Several approaches alone or in combination with other pharmacologic therapies have been shown to enhance function of the NP system: direct administration of native and designer NPs, inhibition of degradation of NPs and their second messenger (cyclic guanosine monophosphate [cGMP]), and stimulation of cGMP generation. Despite increasing numbers of studies using NPs in therapy of acute and chronic CHF, several controversies regarding safety, efficacy, and dosing of NPs need to be addressed. Moreover, further research is warranted to identify the stages and etiologies of CHF that may profit from NP therapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11897-008-0016-y", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2532198", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2540817", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2384951", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2437014", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1033049", 
        "issn": [
          "1546-9530", 
          "1546-9549"
        ], 
        "name": "Current Heart Failure Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "keywords": [
      "congestive heart failure", 
      "chronic congestive heart failure", 
      "natriuretic peptide", 
      "heart failure", 
      "etiology of CHF", 
      "designer natriuretic peptide", 
      "pharmacologic therapy", 
      "volume overload", 
      "antifibrotic action", 
      "cGMP generation", 
      "NP therapy", 
      "pleiotropic molecule", 
      "direct administration", 
      "inhibition of degradation", 
      "therapy", 
      "number of studies", 
      "second messenger", 
      "further research", 
      "vasodilating", 
      "failure", 
      "dosing", 
      "etiology", 
      "peptides", 
      "NP system", 
      "administration", 
      "efficacy", 
      "stimulation", 
      "treatment", 
      "heart", 
      "inhibition", 
      "overload", 
      "safety", 
      "response", 
      "messenger", 
      "controversy", 
      "study", 
      "action", 
      "update", 
      "stage", 
      "combination", 
      "function", 
      "support", 
      "number", 
      "system", 
      "molecules", 
      "research", 
      "insights", 
      "approach", 
      "generation", 
      "degradation"
    ], 
    "name": "Insights into natriuretic peptides in heart failure: An update", 
    "pagination": "97-104", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1038509334"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11897-008-0016-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18765080"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11897-008-0016-y", 
      "https://app.dimensions.ai/details/publication/pub.1038509334"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:56", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_471.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11897-008-0016-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11897-008-0016-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11897-008-0016-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11897-008-0016-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11897-008-0016-y'


 

This table displays all metadata directly associated to this object as RDF triples.

233 TRIPLES      21 PREDICATES      100 URIs      88 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11897-008-0016-y schema:about N0dad6efde73a4947b3d1366fb322d9f1
2 N2037942f021e493fb3c6d60ba45f1a68
3 N2c1d2f1ae0ee47d1a52c47a81b52f7f4
4 N4507ab772b114f5d8ed3249c470fa53a
5 N480bc5084b1f40a394ced3cd13ea6f19
6 N6a13afde0b12441aa4a18173342d7c73
7 N90d8a4ddfd444cd8a0bb9bb8ae5f1772
8 Nac70ad59502f41b69e69f9eedbdf65ef
9 Nae0e06f1595140c1836f8c531e4cdeb6
10 Nb0aa165c3a69458296734d7bbc2f019b
11 Nc023ab0c85fd4e12be9e8395da3a3e8b
12 Nc231dcb577d540bfafb3c9e2f61d502e
13 Nccdef8d012724661b02dc0b57ba6a519
14 Nd21238857c7848aab54ede327610988d
15 Ne0e34f993834419da381f538dd541227
16 Ne248ecc3cdaa43ad897cd3a114cf2732
17 Nf16b6d781a524484806db9e9d2b7e8c4
18 Nfe6bfdfff43f41ed82b282554a994bc5
19 Nff251f8b82494de08da956484bfe5bce
20 Nff715858412f42bc9c51fbfd8cdde0c6
21 anzsrc-for:11
22 anzsrc-for:1102
23 schema:author Nb46867d8e0fe4c2898869e94a13e2903
24 schema:citation sg:pub.10.1007/s11095-007-9286-4
25 sg:pub.10.1023/b:pham.0000048203.30568.81
26 sg:pub.10.1038/nbt1199
27 sg:pub.10.1038/nrd2399
28 schema:datePublished 2008-06
29 schema:datePublishedReg 2008-06-01
30 schema:description Natriuretic peptides (NPs) secreted by the heart in response to volume overload are pleiotropic molecules with vasodilating, diuretic, natriuretic, antiproliferative, and antifibrotic actions. Functioning of the NP system is altered in congestive heart failure (CHF), suggesting that support of the NP system might be beneficial in treatment of acute and chronic CHF. Several approaches alone or in combination with other pharmacologic therapies have been shown to enhance function of the NP system: direct administration of native and designer NPs, inhibition of degradation of NPs and their second messenger (cyclic guanosine monophosphate [cGMP]), and stimulation of cGMP generation. Despite increasing numbers of studies using NPs in therapy of acute and chronic CHF, several controversies regarding safety, efficacy, and dosing of NPs need to be addressed. Moreover, further research is warranted to identify the stages and etiologies of CHF that may profit from NP therapy.
31 schema:genre article
32 schema:isAccessibleForFree false
33 schema:isPartOf N3815e4d54db646acab868e9abd47ad7a
34 Nd404d9878305479eab0988fce43fce2e
35 sg:journal.1033049
36 schema:keywords NP system
37 NP therapy
38 action
39 administration
40 antifibrotic action
41 approach
42 cGMP generation
43 chronic congestive heart failure
44 combination
45 congestive heart failure
46 controversy
47 degradation
48 designer natriuretic peptide
49 direct administration
50 dosing
51 efficacy
52 etiology
53 etiology of CHF
54 failure
55 function
56 further research
57 generation
58 heart
59 heart failure
60 inhibition
61 inhibition of degradation
62 insights
63 messenger
64 molecules
65 natriuretic peptide
66 number
67 number of studies
68 overload
69 peptides
70 pharmacologic therapy
71 pleiotropic molecule
72 research
73 response
74 safety
75 second messenger
76 stage
77 stimulation
78 study
79 support
80 system
81 therapy
82 treatment
83 update
84 vasodilating
85 volume overload
86 schema:name Insights into natriuretic peptides in heart failure: An update
87 schema:pagination 97-104
88 schema:productId N3f4f78e5d8f4412ab3461deef2bd4389
89 N552763fffb934e6686c372bef2df3ccf
90 Nc18abb8002024d3092e34c76087bc24b
91 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038509334
92 https://doi.org/10.1007/s11897-008-0016-y
93 schema:sdDatePublished 2022-08-04T16:56
94 schema:sdLicense https://scigraph.springernature.com/explorer/license/
95 schema:sdPublisher N5d7e3d08eff14b2fad94811dca4a8342
96 schema:url https://doi.org/10.1007/s11897-008-0016-y
97 sgo:license sg:explorer/license/
98 sgo:sdDataset articles
99 rdf:type schema:ScholarlyArticle
100 N0dad6efde73a4947b3d1366fb322d9f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Risk Assessment
102 rdf:type schema:DefinedTerm
103 N2037942f021e493fb3c6d60ba45f1a68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Sensitivity and Specificity
105 rdf:type schema:DefinedTerm
106 N2c1d2f1ae0ee47d1a52c47a81b52f7f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Natriuretic Peptides
108 rdf:type schema:DefinedTerm
109 N3815e4d54db646acab868e9abd47ad7a schema:volumeNumber 5
110 rdf:type schema:PublicationVolume
111 N3f4f78e5d8f4412ab3461deef2bd4389 schema:name doi
112 schema:value 10.1007/s11897-008-0016-y
113 rdf:type schema:PropertyValue
114 N4507ab772b114f5d8ed3249c470fa53a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Prognosis
116 rdf:type schema:DefinedTerm
117 N480bc5084b1f40a394ced3cd13ea6f19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Renin-Angiotensin System
119 rdf:type schema:DefinedTerm
120 N539065422dbf452da1021bd63214fc70 rdf:first sg:person.01021616027.74
121 rdf:rest N7fee365aca1a4619a149ec09ab43ab95
122 N552763fffb934e6686c372bef2df3ccf schema:name dimensions_id
123 schema:value pub.1038509334
124 rdf:type schema:PropertyValue
125 N5d7e3d08eff14b2fad94811dca4a8342 schema:name Springer Nature - SN SciGraph project
126 rdf:type schema:Organization
127 N63adc58aa914468990e6b479c716750b rdf:first sg:person.01001266776.01
128 rdf:rest rdf:nil
129 N6a13afde0b12441aa4a18173342d7c73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Drug Administration Schedule
131 rdf:type schema:DefinedTerm
132 N7fee365aca1a4619a149ec09ab43ab95 rdf:first sg:person.0646060617.69
133 rdf:rest N63adc58aa914468990e6b479c716750b
134 N90d8a4ddfd444cd8a0bb9bb8ae5f1772 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Cyclic GMP
136 rdf:type schema:DefinedTerm
137 Nac70ad59502f41b69e69f9eedbdf65ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Heart Failure
139 rdf:type schema:DefinedTerm
140 Nae0e06f1595140c1836f8c531e4cdeb6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Natriuretic Peptide, C-Type
142 rdf:type schema:DefinedTerm
143 Nb0aa165c3a69458296734d7bbc2f019b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Treatment Outcome
145 rdf:type schema:DefinedTerm
146 Nb46867d8e0fe4c2898869e94a13e2903 rdf:first sg:person.0753213563.81
147 rdf:rest N539065422dbf452da1021bd63214fc70
148 Nc023ab0c85fd4e12be9e8395da3a3e8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Humans
150 rdf:type schema:DefinedTerm
151 Nc18abb8002024d3092e34c76087bc24b schema:name pubmed_id
152 schema:value 18765080
153 rdf:type schema:PropertyValue
154 Nc231dcb577d540bfafb3c9e2f61d502e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Dose-Response Relationship, Drug
156 rdf:type schema:DefinedTerm
157 Nccdef8d012724661b02dc0b57ba6a519 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Natriuretic Peptide, Brain
159 rdf:type schema:DefinedTerm
160 Nd21238857c7848aab54ede327610988d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Acute Disease
162 rdf:type schema:DefinedTerm
163 Nd404d9878305479eab0988fce43fce2e schema:issueNumber 2
164 rdf:type schema:PublicationIssue
165 Ne0e34f993834419da381f538dd541227 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Male
167 rdf:type schema:DefinedTerm
168 Ne248ecc3cdaa43ad897cd3a114cf2732 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Severity of Illness Index
170 rdf:type schema:DefinedTerm
171 Nf16b6d781a524484806db9e9d2b7e8c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Chronic Disease
173 rdf:type schema:DefinedTerm
174 Nfe6bfdfff43f41ed82b282554a994bc5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Drug Therapy, Combination
176 rdf:type schema:DefinedTerm
177 Nff251f8b82494de08da956484bfe5bce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Randomized Controlled Trials as Topic
179 rdf:type schema:DefinedTerm
180 Nff715858412f42bc9c51fbfd8cdde0c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Female
182 rdf:type schema:DefinedTerm
183 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
184 schema:name Medical and Health Sciences
185 rdf:type schema:DefinedTerm
186 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
187 schema:name Cardiorespiratory Medicine and Haematology
188 rdf:type schema:DefinedTerm
189 sg:grant.2384951 http://pending.schema.org/fundedItem sg:pub.10.1007/s11897-008-0016-y
190 rdf:type schema:MonetaryGrant
191 sg:grant.2437014 http://pending.schema.org/fundedItem sg:pub.10.1007/s11897-008-0016-y
192 rdf:type schema:MonetaryGrant
193 sg:grant.2532198 http://pending.schema.org/fundedItem sg:pub.10.1007/s11897-008-0016-y
194 rdf:type schema:MonetaryGrant
195 sg:grant.2540817 http://pending.schema.org/fundedItem sg:pub.10.1007/s11897-008-0016-y
196 rdf:type schema:MonetaryGrant
197 sg:journal.1033049 schema:issn 1546-9530
198 1546-9549
199 schema:name Current Heart Failure Reports
200 schema:publisher Springer Nature
201 rdf:type schema:Periodical
202 sg:person.01001266776.01 schema:familyName Burnett
203 schema:givenName John C.
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001266776.01
205 rdf:type schema:Person
206 sg:person.01021616027.74 schema:familyName Boerrigter
207 schema:givenName Guido
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021616027.74
209 rdf:type schema:Person
210 sg:person.0646060617.69 schema:familyName Mohammed
211 schema:givenName Selma F.
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646060617.69
213 rdf:type schema:Person
214 sg:person.0753213563.81 schema:affiliation grid-institutes:grid.66875.3a
215 schema:familyName Korinek
216 schema:givenName Josef
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753213563.81
218 rdf:type schema:Person
219 sg:pub.10.1007/s11095-007-9286-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019200894
220 https://doi.org/10.1007/s11095-007-9286-4
221 rdf:type schema:CreativeWork
222 sg:pub.10.1023/b:pham.0000048203.30568.81 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004340827
223 https://doi.org/10.1023/b:pham.0000048203.30568.81
224 rdf:type schema:CreativeWork
225 sg:pub.10.1038/nbt1199 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015601292
226 https://doi.org/10.1038/nbt1199
227 rdf:type schema:CreativeWork
228 sg:pub.10.1038/nrd2399 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051687311
229 https://doi.org/10.1038/nrd2399
230 rdf:type schema:CreativeWork
231 grid-institutes:grid.66875.3a schema:alternateName Mayo Clinic and Foundation, 200 First Street SW, 55905, Rochester, MN, USA
232 schema:name Mayo Clinic and Foundation, 200 First Street SW, 55905, Rochester, MN, USA
233 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...